Korea's Green Cross Files For Biobetter Of Shire's Hunter Syndrome Therapy Elaprase; Seeks Global Partners
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's leading vaccine manufacturer Green Cross Corp. took a step forward in the biosimilars sector by submitting a marketing application to Korea FDA for a biobetter of Shire PLC's Elaprase (idursulfase) for Hunter syndrome. And now the company is looking for foreign partners